Human bone has the right mineral composition to be easily broken down and allografts’ natural micro and macroporosity are highly osteoconductive. However, autografts are subject to availability, safety concerns, and higher morbidity as a result of the harvesting process.
Therefore, allografts are often used in such surgeries and procedures to avoid a second surgery site and decrease the patient’s hospital stay as well as time spent in the Operating Theatre.
All Leader Biomedical allografts are processed with our proprietary eCOO® Technology, a mild and efficient platform using supercritical carbon dioxide (scCO2) to clean, sterilise, and impregnate human and animal-derived bone and tissue with limited use of chemicals.
scCO2 minimally aﬀects the structural integrity of bone and tissue grafts when compared to conventional processing techniques. Furthermore, scCO2 treatment removes medullary tissues responsible for adverse immune response.